Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Ascendis Pharma A (ASND) over the last 7 years, with Sep 2025 value amounting to $2.2 million.

  • Ascendis Pharma A's Depreciation & Amortization (CF) rose 10.28% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year increase of 20.75%. This contributed to the annual value of $18.7 million for FY2024, which is 5.85% down from last year.
  • Per Ascendis Pharma A's latest filing, its Depreciation & Amortization (CF) stood at $2.2 million for Q3 2025, which was down 4.77% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Depreciation & Amortization (CF) ranged from a high of $4.8 million in Q1 2022 and a low of $2.0 million during Q3 2024.
  • Its 3-year average for Depreciation & Amortization (CF) is $3.3 million, with a median of $3.2 million in 2023.
  • Per our database at Business Quant, Ascendis Pharma A's Depreciation & Amortization (CF) spiked by 97.54% in 2021 and then crashed by 45.66% in 2023.
  • Over the past 5 years, Ascendis Pharma A's Depreciation & Amortization (CF) (Quarterly) stood at $4.8 million in 2021, then fell by 3.02% to $4.6 million in 2022, then plummeted by 45.66% to $2.5 million in 2023, then spiked by 85.52% to $4.7 million in 2024, then climbed by 10.28% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.3 million for Q2 2025, and $4.7 million during Q1 2025.